Amend 003 - Hepatitis A Adult and Pediatric - GlaxoSmithKline Inc.
Status Awarded
Contract number E60PH-22HEPA/002/PH
Solicitation number E60PH-22HEPA/A
Publication date
Contract award date
Last amendment date
Amendment value
Status Awarded
Contract number E60PH-22HEPA/002/PH
Solicitation number E60PH-22HEPA/A
Publication date
Contract award date
Last amendment date
Amendment value
This contract was awarded to:
The contract will be for a period of 36 month(s), from 2022/03/04 to 2025/03/31.
CAD 3,152,686.13